+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Recipharm AB (RECI B) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 53 Pages
  • May 2020
  • GlobalData
  • ID: 4284780
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Recipharm AB (RECI B) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Recipharm AB (Recipharm) is a contract development and manufacturing organization (CDMO) that offers manufacturing, and development and technology services. The company's manufacturing services include contract manufacturing of pharmaceuticals such as semi-solids, and oral liquids, solid dose, sterile products, besides clinical trial materials including APIs and other drugs. Recipharm’s development and technology services supports customers from initial product concept to the approved commercial pharmaceutical drug. It includes services such as raw material supply, formulation, validated analytical methods, among others. The company operates in the UK, Germany, Spain, Italy, Sweden, France, Portugal, India, Israel and the US. Recipharm is headquartered in Stockholm, Sweden.

Recipharm AB Key Recent Developments

May 07, 2020: Recipharm publishes its interim report January-March 2020
May 07, 2020: Recipharm secures supply of drug substance and commences manufacture of chloroquine phosphate
Apr 08, 2020: Recipharm’s board of directors decides to withdraw dividend proposal
Mar 06, 2020: Recipharm completes delisting of Consort Medical
Mar 06, 2020: Recipharm notes an increased demand for Chloroquine Phosphate

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table of Contents

List of TablesList of Figures
Section 1 - About the Company
  • Recipharm AB - Key Facts
  • Recipharm AB - Key Employees
  • Recipharm AB - Key Employee Biographies
  • Recipharm AB - Major Products and Services
  • Recipharm AB - History
  • Recipharm AB - Company Statement
  • Recipharm AB - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries

Section 2 – Company Analysis
  • Company Overview
  • Recipharm AB - Business Description
  • Business Segment: D&T
  • Overview
  • Performance
  • Business Segment: MFG-SI
  • Overview
  • Performance
  • Business Segment: MFG-SO
  • Overview
  • Performance
  • Geographical Segment: France
  • Performance
  • Geographical Segment: Germany
  • Performance
  • Geographical Segment: India
  • Performance
  • Geographical Segment: Italy
  • Performance
  • Geographical Segment: Other
  • Performance
  • Geographical Segment: Portugal
  • Performance
  • Geographical Segment: Spain
  • Performance
  • Geographical Segment: Sweden
  • Performance
  • Geographical Segment: UK
  • Performance
  • Recipharm AB - Corporate Strategy
  • Recipharm AB - SWOT Analysis
  • SWOT Analysis - Overview
  • Recipharm AB - Strengths
  • Recipharm AB - Weaknesses
  • Recipharm AB - Opportunities
  • Recipharm AB - Threats
  • Recipharm AB - Key Competitors

Section 3 – Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts

Section 4 – Company’s Lifesciences Financial Deals and Alliances
  • Recipharm AB, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
  • Recipharm AB, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
  • Recipharm AB, Recent Deals Summary

Section 5 – Company’s Recent Developments
  • May 07, 2020: Recipharm publishes its interim report January-March 2020
  • May 07, 2020: Recipharm secures supply of drug substance and commences manufacture of chloroquine phosphate
  • Mar 06, 2020: Recipharm completes delisting of Consort Medical
  • Mar 06, 2020: Recipharm notes an increased demand for Chloroquine Phosphate
  • Feb 20, 2020: Recipharm publishes report for the fourth quarter and full year 2019
  • Feb 07, 2020: Recipharm announces that Consort Medical applies for delisting
  • Feb 05, 2020: Consort Medical becomes part of the Recipharm Group
  • Dec 09, 2019: Recipharm invests in its US inhalation development service
  • Nov 18, 2019: Recipharm to communicate new financial targets on Capital Markets Day
  • Nov 14, 2019: Recipharm joins the AMR Industry Alliance

Section 6 – Appendix
  • Methodology
  • Ratio Definitions
  • About the Publisher
  • Contact
  • Disclaimer

List of Tables
  • Recipharm AB, Key Facts
  • Recipharm AB, Key Employees
  • Recipharm AB, Key Employee Biographies
  • Recipharm AB, Major Products and Services
  • Recipharm AB, History
  • Recipharm AB, Other Locations
  • Recipharm AB, Subsidiaries
  • Recipharm AB, Key Competitors
  • Recipharm AB, Ratios based on current share price
  • Recipharm AB, Annual Ratios
  • Recipharm AB, Annual Ratios (Cont...1)
  • Recipharm AB, Annual Ratios (Cont...2)
  • Recipharm AB, Interim Ratios
  • Recipharm AB, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
  • Recipharm AB, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
  • Recipharm AB, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios

List of Figures
  • Recipharm AB, Performance Chart (2015 - 2019)
  • Recipharm AB, Ratio Charts
  • Recipharm AB, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
  • Recipharm AB, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020

Samples

Loading
LOADING...

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Vetter Pharma-Fertigung GmbH & Co KG
  • Patheon NV
  • Iconovo AB
  • Fareva SA
  • F. Hoffmann-La Roche Ltd
  • Corden Pharma International GmbH
  • Catalent Inc
  • Boehringer Ingelheim International GmbH